Items tagged with Scientific research
TB study reveals potential targets to treat and control infection using cutting-edge technology (post)
San Antonio, Texas (February 11, 2020) – Researchers at the Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute (Texas Biomed) may have found a new pathway to treat and control tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb). Using single-cell RNA sequencing (scRNAseq), a next-generation sequencing technology, scientists were able to further define the mechanisms that lead to TB infection and latency. Co-led by Deepak Kaushal, Ph.D., Director of the SNPRC, this is the first study that used scRNAseq to study TB in macaques in depth. Results from the study were published in Cell Host & Microbe.
TB: New biomarker indicates individual treatment duration (post)
The treatment of tuberculosis (TB) is long, demanding, and expensive. In particular, the ever increasing emergence of resistant tuberculosis bacteria requires a lot of patience: In these cases, the WHO generally recommends a standard treatment duration of at least 18 months, as there are no reliable biomarkers for an early termination. Under the leadership of the DZIF scientists at the Research Center Borstel, six years of research have now succeeded in identifying a biomarker that points to an individual end of therapy based on the activity of 22 genes. In many cases, this probably allows the treatment to be shortened safely.
Disease tolerance: Skeletons reveal humans evolved to fight pathogens (post)
As Covid-19 impacts lives around the world, a new skeleton study is reconstructing ancient pandemics to assess human's evolutionary ability to fight off leprosy, tuberculosis and treponematoses with help from declining rates of transmission when the germs became widespread.
Study could explain tuberculosis bacteria paradox (post)
Tuberculosis bacteria have evolved to remember stressful encounters and react quickly to future stress, according to a study by computational bioengineers at Rice University and infectious disease experts at Rutgers New Jersey Medical School (NJMS).
Research pinpoints unique drug target in antibiotic resistant bacteria (post)
Researchers have identified a critical mechanism that allows deadly bacteria to gain resistance to antibiotics.
HIV treatment helps prevent active TB (post)
Antiretroviral treatment (ART) reduces the risk of developing active tuberculosis (TB) in people also infected with HIV-1, by dampening the activation of the body’s immune response. These findings could help improve treatment for both conditions in the future.
Study illuminates role of gut microbes in the response to TB treatment (post)
Gut bacteria play an important role in the body’s response to treatment for tuberculosis (TB), according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering. Because current treatments for TB involve long courses of antibiotics, which are known to disrupt the balance of microbes in the gut, a better understanding of these interactions may help in predicting outcomes to therapy and suggest ways to improve it.
How one patient’s rare mutation helped solve a mycobacterial mystery (post)
Just because you are exposed to a pathogen does not mean you will become sick. Increasingly, scientists have shown that genetics play a central role in determining whether the pathogens that cause a wide range of disease—including influenza, warts, and COVID-19—end up causing serious diseases.
TB Alliance and GSK announce partnership to develop new TB therapeutics (post)
NEW YORK (March 18, 2021) — TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that can improve the treatment of tuberculosis (TB).
TB Alliance issues call for researchers to access TB biomarker repository (post)
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with Knowledge of Tuberculosis Biomarkers) database of high-quality patient specimens from late-stage TB drug clinical trials. In making this repository available, MARK-TB is enabling the discovery and qualification of biomarkers to speed clinical development of improved tuberculosis (TB) treatments for both drug-sensitive and multidrug-resistant TB, as well as potentially improving the care of TB patients.
Page 53 of 74 · Total posts: 0
←First 52 53 54 Last→